September 12, 2025

Cardiovascular Effects of GLP-1 Receptor Agonists in Non-Diabetic Adults With Obesity: A Systematic Literature Review

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review reveals cardiovascular benefits of GLP-1 receptor agonists in non-diabetic adults, highlighting semaglutide's strong outcomes.

GLP-1 receptor agonists improved cardiovascular outcomes in non-diabetic adults with obesity, suggesting cardioprotective potential.
Key metrics include reductions in NT-proBNP and CRP, with semaglutide showing the most consistent cardiovascular benefits.
Systematic literature review assessed 15 clinical trials to evaluate cardiovascular impact beyond weight loss in non-diabetic populations.
Findings indicate a strong association between weight loss and cardiovascular indicators, highlighting the need for further dedicated trials.

Mariam Abdeen (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review reveals cardiovascular benefits of GLP-1 receptor agonists in non-diabetic adults, highlighting semaglutide's strong outcomes.